# MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV

> **NCT01970410** · PHASE4 · COMPLETED · sponsor: **Providence Health & Services** · enrollment: 55 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** teriflunomide

## Key facts

- **NCT ID:** NCT01970410
- **Lead sponsor:** Providence Health & Services
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2021-04-30
- **Final completion:** 2022-02-14
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2023-01-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01970410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01970410, "MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01970410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*